A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and efficacy of two dose levels of
Naglazyme in infants under the age of one year who have MPS VI by monitoring physical
appearance, x-ray of the skeletal system and growth.